GILEAD SCIENCES, INC. Future Amortization Expense, Year Three (Deprecated 2012-01-31)
GILEAD SCIENCES, INC. (GILD) reported Future Amortization Expense, Year Three (Deprecated 2012-01-31) of $73.26 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseYearThree · last filed 2012-05-04
- GILEAD SCIENCES, INC. future amortization expense, year three (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $73.26M, a 19.71% decline year-over-year.
- GILEAD SCIENCES, INC. future amortization expense, year three (deprecated 2012-01-31) for the quarter ending 2011-12-31 was -$24.51M.
- GILEAD SCIENCES, INC. future amortization expense, year three (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $0.00.
- GILEAD SCIENCES, INC. future amortization expense, year three (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $0.00.
- GILEAD SCIENCES, INC. future amortization expense, year three (deprecated 2012-01-31) for fiscal 2011 was $66.73M, a 18.70% decline from fiscal 2010.
- GILEAD SCIENCES, INC. future amortization expense, year three (deprecated 2012-01-31) for fiscal 2010 was $82.09M.
| Period end | Future Amortization Expense, Year Three (Deprecated 2012-01-31) 3 month | Future Amortization Expense, Year Three (Deprecated 2012-01-31) 6 month | Future Amortization Expense, Year Three (Deprecated 2012-01-31) 9 month | Future Amortization Expense, Year Three (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $73.26M 10-Q · filed 2012-05-04 | $48.75M derived: sum of 2 quarters · filed 2012-05-04 | $48.75M derived: sum of 3 quarters · filed 2012-05-04 | $48.75M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | -$24.51M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$24.51M derived: sum of 2 quarters · filed 2012-02-23 | -$24.51M derived: sum of 3 quarters · filed 2012-02-23 | $66.73M 10-K · filed 2012-02-23 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $0.00 derived: sum of 2 quarters · filed 2011-11-04 | $91.25M 10-Q · filed 2011-11-04 | $78.03M derived: sum of 4 quarters · filed 2011-11-04 |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $91.25M 10-Q · filed 2011-08-05 | $78.03M derived: sum of 3 quarters · filed 2011-08-05 | $78.03M derived: sum of 4 quarters · filed 2011-08-05 |
| 2011-03-31 | $91.25M 10-Q · filed 2011-05-09 | $78.03M derived: sum of 2 quarters · filed 2011-05-09 | $78.03M derived: sum of 3 quarters · filed 2011-05-09 | |
| 2010-12-31 | -$13.22M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | -$13.22M derived: sum of 2 quarters · filed 2011-02-28 | $82.09M 10-K · filed 2011-02-28 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $95.30M 10-Q · filed 2010-11-08 | ||
| 2010-06-30 | $95.30M 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |